Faculty of Law, Institute of Population Health
University of Ottawa
57 Louis Pasteur St Ottawa, Ontario K1N 6N5
NBER Working Papers and Publications
|September 2014||Poor Quality Drugs and Global Trade: A Pilot Study|
with Roger Bate, Ginger Zhe Jin, Aparna Mathur: w20469
Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries. We find that 10.9% of those products fail a basic assessment of active pharmaceutical ingredients (API), and the majority of the failures are substandard (7%) as they contain some correct API but the amount of API is under-dosed. The distribution of these substandard products is not random: they are more likely to be found as unregistered products in Africa than in India or non-African countries. Since this finding is robus...
Published: Roger Bate & Ginger Zhe Jin & Aparna Mathur & Amir Attaran, 2016. "Poor-Quality Drugs and Global Trade: A Pilot Study," American Journal of Health Economics, vol 2(3), pages 373-398.